Home > Journals > Acta Phlebologica > Past Issues > Acta Phlebologica 2013 December;14(3) > Acta Phlebologica 2013 December;14(3):115-21

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions
Share

 

ORIGINAL ARTICLES   

Acta Phlebologica 2013 December;14(3):115-21

Copyright © 2014 EDIZIONI MINERVA MEDICA

language: English

Pulmonary embolism, metalloproteinases and neutrophil gelatinase associated lipocalin

Busceti M. T. 1, Grande R. 1, Amato B. 2, 3, Gasbarro V. 3, 4, Buffone G. 1, Amato M. 2, Gallelli L. 3, Serra R. 1, 3, De Franciscis S. 1, 3

1 Department of Medical and Surgical Science Magna Graecia University, Catanzaro, Italy; 2 Department of Clinical Medicine Federico II University, Naples, Italy; 3 Interuniversity Center of Phlebolymphology International Research and Educational Program in Clinical and Experimental Biotechnology Magna Graecia University, Catanzaro, Italy; 4 Department of Vascular Surgery Ferrara University, Ferrara, Italy


PDF


Aim: Pulmonary embolism (PE) is a common disease related to significant morbidity and mortality. Several prognostic models have been developed to assess the risk of complications in patients with PE. Metalloproteinases (MMPs) seem to be involved in both respiratory and endothelial dysfunction in PE. In this study we evaluated plasma levels of MMP-2, MMP-9 and Neutrophil Gelatinase Associated Lipocalin (NGAL) in patients with PE.
Methods: An open label, parallel groups study in three clinical departments was conducted between January 2010-December 2012. Patients eligible for the study were of both sexes, from 20 up to 70 years, with a diagnosis of PE. ELISA testing was used to determine the concentration of MMP-2, MMP-9, NGAL in plasma of enrolled patients.
Results: Seventeen patients with PE (14M, 3F) were enrolled. Patients were divided in two groups according to Pulmonary Embolism Severity Index (PESI): Group I (high risk); Group II (low risk); Group III (healthy volunteers, as control group). ELISA findings revealed significantly higher levels (P<0.01) of MMP-2, MMP-9 and NGAL in plasma of PE patients (Group I and II) respect to control patients (Group III) and the levels of MMP-9 and NGAL were also significantly higher in patients at high risk (P<0.01) (Group I).
Conclusion: This study showed a role of the dosage of plasmatic MMPs and NGAL in order to better classify the prognosis of patients with PE.

top of page